High-dose interferon versus GM2 vaccine in high-risk malignant melanoma.
作者信息
Wilson K
出版信息
J Clin Oncol. 2001 Dec 1;19(23):4350.
PMID:11731522
Abstract
摘要
相似文献
1
High-dose interferon versus GM2 vaccine in high-risk malignant melanoma.高剂量干扰素与GM2疫苗治疗高危恶性黑色素瘤的对比研究
J Clin Oncol. 2001 Dec 1;19(23):4350.
2
[Interferon: therapy in patients with cutaneous malignant melanoma in adjuvant setting].[干扰素：皮肤恶性黑色素瘤患者辅助治疗]
Pol Merkur Lekarski. 2003 Jul;15(85):5-8.
3
Immunopharmacologic analysis of an autologous, hapten-modified human melanoma vaccine.一种自体、半抗原修饰的人黑色素瘤疫苗的免疫药理学分析。
J Clin Oncol. 2004 Feb 1;22(3):403-15. doi: 10.1200/JCO.2004.06.043. Epub 2003 Dec 22.
4
Multidisciplinary treatment of primary melanoma.原发性黑色素瘤的多学科治疗
Surg Clin North Am. 2009 Feb;89(1):267-81, xi. doi: 10.1016/j.suc.2008.11.002.
5
Adjuvant therapy for malignant melanoma.恶性黑色素瘤的辅助治疗
Expert Rev Anticancer Ther. 2004 Oct;4(5):823-35. doi: 10.1586/14737140.4.5.823.
6
The current status of evaluation and treatment of high-risk cutaneous melanoma: therapeutic breakthroughs remain elusive.高危皮肤黑色素瘤的评估与治疗现状：治疗突破仍难以实现。
Arch Dermatol. 2007 Jun;143(6):785-7. doi: 10.1001/archderm.143.6.785.
7
Overlapping human leukocyte antigen class I/II binding peptide vaccine for the treatment of patients with stage IV melanoma: evidence of systemic immune dysfunction.用于治疗IV期黑色素瘤患者的重叠人白细胞抗原I/II类结合肽疫苗：全身免疫功能障碍的证据
Cancer. 2007 Jul 1;110(1):203-14. doi: 10.1002/cncr.22744.
8
Cutaneous melanoma: available therapy for metastatic disease.
Dermatol Ther. 2006 Jan-Feb;19(1):19-25. doi: 10.1111/j.1529-8019.2005.00052.x.
9
[Adjuvant interferon treatment of melanoma].[黑色素瘤的辅助干扰素治疗]
Magy Onkol. 2003;47(1):105-7. Epub 2003 Apr 18.
10
Pretreatment levels of peripheral neutrophils and leukocytes as independent predictors of overall survival in patients with American Joint Committee on Cancer Stage IV Melanoma: results of the EORTC 18951 Biochemotherapy Trial.外周血中性粒细胞和白细胞的预处理水平作为美国癌症联合委员会IV期黑色素瘤患者总生存的独立预测因素：欧洲癌症研究与治疗组织18951生物化疗试验的结果
J Clin Oncol. 2007 Apr 20;25(12):1562-9. doi: 10.1200/JCO.2006.09.0274.
引用本文的文献
1
Validation of Melanoma Immune Profile (MIP), a Prognostic Immune Gene Prediction Score for Stage II-III Melanoma.验证黑色素瘤免疫特征（MIP），一种用于 II-III 期黑色素瘤的预后免疫基因预测评分。
Clin Cancer Res. 2019 Apr 15;25(8):2494-2502. doi: 10.1158/1078-0432.CCR-18-2847. Epub 2019 Jan 15.
2
Adjuvant interferon alfa for melanoma.黑色素瘤的辅助性干扰素α治疗
Curr Oncol. 2010 Jun;17(3):6-7. doi: 10.3747/co.v17i3.511.
Zotero 插件